Esperion therapeutics, inc. (ESPR)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities
Net income (loss)

-78,249

-61,946

-68,377

-54,221

87,379

-60,039

-49,911

-45,730

-46,130

-37,891

-45,219

-43,337

-40,541

-28,956

-17,402

-14,035

-14,585

-13,122

-12,801

-12,395

-11,466

-9,457

-9,806

-9,238

-7,874

Adjustments to reconcile net income (loss) to net cash used in operating activities:
Depreciation expense

106

82

92

55

71

109

67

63

61

104

62

65

69

62

63

63

64

67

54

56

59

56

51

41

12

Amortization of debt discount

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

6

6

7

7

7

8

-

-

-

-

Amortization of debt issuance costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5

6

7

8

8

8

8

-

-

-

-

Accretion of premiums and discounts on investments

73

60

19

46

75

-

-

-

-

-20

-63

-103

-148

-248

-274

-238

-254

-251

-218

-151

-27

-42

-54

-53

-53

Non-cash interest expense related to the revenue interest liability

4,171

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

7,053

6,358

6,327

6,563

6,636

6,829

5,495

5,723

5,921

4,534

4,941

4,980

4,150

3,571

3,709

4,121

4,556

4,385

3,371

2,898

2,072

1,053

950

935

741

Loss related to assets held for sale

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-23

-6

Loss on sale of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1

0

10

-11

Changes in assets and liabilities:
Prepaids and other assets

2,538

1,594

3,642

-546

-1,294

-2,383

282

4,564

421

273

-88

-2,589

4,135

-1,372

1,456

-674

451

-1,116

2,318

-787

860

-752

24

-36

1,028

Deferred revenue

-982

-466

-981

-982

4,581

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Inventories

1,841

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-13,650

5,103

-4,453

-5,156

-11,549

26,254

-3,915

10,520

-8,413

852

787

7,081

7,038

2,812

217

26

833

-1,253

-1,345

452

813

-1,350

-738

1,948

-159

Other accrued liabilities

16,656

-1,614

9,028

-768

3,354

-4,110

11,096

-5,153

5,761

-2,178

3,394

2,291

-1,045

4,610

281

1,594

-487

42

979

-578

76

680

866

134

-866

Net cash (used in) provided by operating activities

-69,347

-49,994

-58,029

-54,009

91,691

-28,692

-37,527

-39,198

-43,221

-34,874

-35,884

-26,228

-34,316

-16,316

-14,304

-7,307

-9,803

-8,449

-11,830

-8,614

-9,263

-8,208

-8,631

-6,078

-9,104

Purchases of investments

4,420

-

-

-

-

0

4,941

5,920

14,620

6,604

176,204

8,578

28,191

33,704

50,904

42,370

70,252

38,364

74,061

97,780

70,354

43,288

0

1,800

3,000

Proceeds from sales/maturities of investments

31,200

5,000

21,675

26,950

45,885

38,673

45,015

37,490

44,903

55,003

48,681

35,686

44,373

41,545

63,974

61,633

40,290

43,922

36,875

27,182

12,813

4,425

1,000

2,500

4,426

Purchase of property and equipment

191

172

358

234

189

-

-

-

-

0

0

5

14

-

-

-

-

228

76

14

7

20

215

365

273

Net cash provided by investing activities

26,589

-2,868

-5,313

26,716

45,696

38,568

40,028

31,570

30,283

48,399

-127,523

27,103

16,168

7,752

13,070

19,258

-29,962

5,345

-37,259

-70,606

-57,548

-38,883

785

347

1,153

Financing activities
Proceeds from issuance of common stock, net of issuance costs

25,000

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

0

-168

190,150

-

-

-

-

Proceeds from exercise of common stock options

1,014

7,014

1,201

1,887

1,669

342

27

1,636

9,738

435

410

55

267

0

10

8

27

0

379

534

264

166

165

90

52

Payments on long-term debt

-

-

-

-

-

0

153

451

445

437

431

424

417

411

404

398

391

-

-

-

-

-

-

-

-

Net cash provided by financing activities

26,014

7,014

976

126,536

1,669

342

-126

1,185

9,293

-81

164,058

-369

-150

-411

-394

-390

-364

-384

126

366

190,414

91,897

134

5,037

52

Net increase (decrease) in cash and cash equivalents

-16,744

-45,848

-62,366

99,243

139,056

10,218

2,375

-6,443

-3,645

13,444

651

506

-18,298

-8,975

-1,628

11,561

-40,129

-3,488

-48,963

-78,854

123,603

44,806

-7,712

-694

-7,899

Supplemental disclosure of cash flow information:
Purchase of property and equipment not yet paid

408

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non cash right of use asset

91

0

5

1

25

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Offering costs not yet paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

173

-

-

-

-